These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34656146)

  • 1. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    Coulson-Gilmer C; Morgan RD; Nelson L; Barnes BM; Tighe A; Wardenaar R; Spierings DCJ; Schlecht H; Burghel GJ; Foijer F; Desai S; McGrail JC; Taylor SS
    J Exp Clin Cancer Res; 2021 Oct; 40(1):323. PubMed ID: 34656146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
    Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer.
    Acharya G; Mani C; Sah N; Saamarthy K; Young R; Reedy MB; Sobol RW; Palle K
    Cell Death Discov; 2024 Jun; 10(1):278. PubMed ID: 38862485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
    Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A
    Front Oncol; 2021; 11():745981. PubMed ID: 34778062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.
    Jain A; Agostini LC; McCarthy GA; Chand SN; Ramirez A; Nevler A; Cozzitorto J; Schultz CW; Lowder CY; Smith KM; Waddell ID; Raitses-Gurevich M; Stossel C; Gorman YG; Atias D; Yeo CJ; Winter JM; Olive KP; Golan T; Pishvaian MJ; Ogilvie D; James DI; Jordan AM; Brody JR
    Cancer Res; 2019 Sep; 79(17):4491-4502. PubMed ID: 31273064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
    Golder A; Nelson L; Tighe A; Barnes B; Coulson-Gilmer C; Morgan RD; McGrail JC; Taylor SS
    NAR Cancer; 2022 Dec; 4(4):zcac036. PubMed ID: 36381271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
    Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
    Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
    Gravells P; Grant E; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic PARG inhibitor sensitivity is mimicked by
    Coulson-Gilmer C; Littler S; Barnes BM; Brady RM; Anagho HA; Pillay N; Dey M; Macmorland W; Bronder D; Nelson L; Tighe A; Lin WH; Morgan RD; Unwin RD; Nielsen ML; McGrail JC; Taylor SS
    NAR Cancer; 2024 Sep; 6(3):zcae030. PubMed ID: 39015544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
    Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
    Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
    Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
    Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
    Harrision D; Gravells P; Thompson R; Bryant HE
    Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
    Feng X; Koh DW
    Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAD
    Li J; M Saville K; Ibrahim M; Zeng X; McClellan S; Angajala A; Beiser A; Andrews JF; Sun M; Koczor CA; Clark J; Hayat F; Makarov MV; Wilk A; Yates NA; Migaud ME; Sobol RW
    NAR Cancer; 2021 Dec; 3(4):zcab044. PubMed ID: 34806016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.